Fortrea Holdings is a contract research organization providing phase I through IV biopharmaceutical product and medical device services, patient access solutions and other services. Co. provides its pharmaceutical, biotechnology, and medical device customers with clinical pharmacology, clinical development, and other service capabilities. Co. manages its business in two segments: Clinical Services, which brings solutions to market which include clinical pharmacology and clinical development capabilities; as well as Enabling Services, which provides patient access and technology solutions which can be deployed across any of its global solutions depending on the scope of its customers' needs. The FTRE average annual return since 2023 is shown above.
The Average Annual Return on the FTRE average annual return since 2023 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether FTRE average annual return since 2023 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the FTRE average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|